1. Thielman NM, Wilson KH. Antibiotic-associated colitis. In Mandell GL, Bennett JE, Dolin R (eds). Principles and Practice of Infectious Diseases. 7.th eds, Churchill Livingstone Elsevier,
Philadelphia, 2010: 1375-87.
2. Högenauer C, Langner C, Beubler E, et al. Klebsiella oxytoca as a causative organism of antibiotic-associated hemorrhagic colitis. N Engl J Med 2006; 355: 2418-26.
3. Sullivan A, Edlund C, Nord CE. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis 2001; 1: 101-114.
4. Beaugerie L, Petit J-C. Antibiotic-associated diarrhoea. Best Practice & Research Clinical Gastroenterology 2004; 18: 337-352.
5. Högenauer C, Hammer HF, Krejs GJ, Reisinger EC. Mechanisms and management of antibiotic-associated diarrhea. Clin Infect Dis 1998; 27: 702-710.
6. Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 2002 ; 346: 334-39.
7. Britton RA, Young VB. Interaction between the intestinal microbiota and host in Clostridium difficile colonization resistance. Trends in Microbiology 2012; 20: 313-19.
8. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994; 330: 257-62.
9. Hookman P, Barkin JS. Clostridium difficile associated infection, diarrhea and colitis. World J Gastroenterol 2009; 15: 1554-80.
10. Fekety R. Guidelines for diagnosis and management of Clostridium difficile associated diarrhea and colitis. Am J Gastroenterol 1997; 92: 739-50.
11. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366:
1079-84.
12. Heimesaat MM, Granzow K, Leidinger H, Liesenfeld O. Prevalence of Clostridium difficile toxins A and B and Clostridium perfringens enterotoksin A in stool samples of patients with antibi-
otic-associated diarrhea. Infection 2005; 33: 340-44.
13. Asha NJ, Tompkins D, Wilcox MH. Comparative analysis of prevalence, risk factors and molecular epidemiology of antibiotic associated diarrhea due to Clostridium difficile, Clostridium
perfringens, Staphylococcus aureus. J Clin Microbiol 2006; 44: 2785-91.
14. Gorkiewicz G. Nosocomial and antibiotic-associated diarrhoea caused by organisms other than Clostridium difficile. International J Antimicrobial Agents 2009; 33(S1): S37-S41.
15. Boyce JM, Havil NL. Nosocomial antibiotic-associated diarrhea associated with enterotoxin-producing strains of meticillin-resistant Staphylococcus aureus. Am J Gastroenterol 2005; 100:
1828-34.
16. Beaugerie L, Metz M, Barbut F, et al. Klebsiella oxytoca as an agent of antibiotic associated hemorrhagic colitis. Clin Gastroenterol Hepatol 2003; 1: 370-76.
17. Zollner-Schwetz I, Högenauer C, Joainig M, et al. Role of Klebsiella oxytoca in antibiotic-associated diarrhea. Clin Infect Dis 2008; 47: e74-8.
18. Yilmaz M, Bilir YA, Aygün G, Erzin Y, Ozturk R, Çelik AF. Prospective observational study on antibiotic-associated bloody diarrhea: report of 21 cases with a long-term follow-up from Turkey.
Eur J Gastroenterol Hepatol 2012; 24: 688-94.
19. Levine J, Dykoski RK, Janoff EN. Candida-associated diarrhea : a syndrome in search of credibility. Clin İnfect Dis 1995; 21: 881-86.
20. Krause R, Reisinger EC. Candida and antibiotic-associated diarrhoea. Clin Microbiol Infect 2005; 11: 1-2.
21. Hove H, Tvede M, Brobech-Mortensen P. Antibiotic associated diarrhoea, Clostridium difficile and short-chain fatty acids. Scand J Gastroenterol 1996; 31: 688-93.
22. Pasquale TR, Tan JS. Nonantimicrobial effects of antibacterial agents. Clin Infect Dis 2005; 40: 127-35.
23. Zilberberg MD, Shorr AF, Kollef MH. Increase in adult Clostridium difficile-related hospitalisations and case-fatality rate United States, 2000-2005. Emerg Infect Dis 2008; 14: 929-31.
24. McDonald L, Gerding D, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America
(IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018; 66(7): e1-e48.
25. Aygün G, Aslan M, Yaşar H, Altaş K. Antibiyotik ilişkili ishal olgularında Clostridium difficile toksin A+B araştırılması. Türk Mikrobiyol Cem Derg 2003; 33: 39-41.
26. Kelly CP, LaMont JT. Clostridium difficile-more difficile than ever. N Eng J Med. 2008; 359: 1932-40.
27. Efron PA, Mazuski JE. Clostridium difficile colitis. Surg Clin North America 2009; 89: 483-500.
28. Harbarth S, Samore MH, Carmelli Y. Antibiotic prophylaxis and the risk of Clostridium difficile-associated diarrhoea. J Hosp Infect 2001; 48: 93-97.
29. Aygün G. Clostridium difficile mikrobiyolojisi. (In) Öztürk R (ed) Yeni ve Yeniden Gündeme Gelen İnfeksiyonlar: Clostridium difficile enfeksiyonları. Bilimsel Tıp Yayınevi, Ankara 2005: 16-
20.
30. Lyerly DM, Krivan HC, Wilkins TD. Clostridium difficile: Its disease and toxins. Clin Microbiol Rev 1988; 1: 1-18.
31. Al Saif N, Brazier JS. The distribution of Clostridium difficile in the environment of South Wales. J Med Microbiol 1996; 45: 133-37.
32. Karlstrom O, Fryklund B, Tullus K, Burman LG. A prospective nationwide study of Clostridium difficile-associated diarrheain Sweden. The Swedish C.difficile Study Group. Clin Infect Dis
1998; 26: 141-45.
33. Hirschhorn LR, Trnka Y, Onderdonk A, et al. Epidemiology of comminity-acquired Clostridium difficile-associated diarrhea. J Infect Dis 1994; 169: 127-33.
34. Dial S, Delaney JAC, Barkun AN, Suissa S. Use of gastric asid-supressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005; 294: 2989-95.
35. Noren T, Akerlund T, Bäck E, et al. Molecular epidemiology of hospital-associated and community-acquired Clostridium difficile infection in a Swedish county. J Clin Microbiol 2004; 42:
3635-43.
36. Kato H, Kita H, Karasawa T, et al. Colonisation and transmission of Clostridium difficile in healthy individuals examined by PCR ribotyping and pulsed-field gel electrophoresis. J Med Mic-
robiol 2001; 50: 720-27.
37. Silva Junior M. Recent changes in Clostridium difficile infection. Einstein 2012; 10: 105-109.
38. Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis 2005; 5: 549-57.
39. Loo VG, Bourgault AM, Poirier L, et al. Host and Pathogen Factors for Clostridium difficile Infection and Colonization. N Engl J Med 2011; 365(18): 1693-1703.
40. Anand A, Glatt AE. Clostridium difficile Infection Associated with Antineoplastic Chemotherapy: A Review. Clin Infect Dis 1993; 17(1): 109-113.
41. Kwon JH, Olsen MA, and Dubberke ER. The morbidity, mortality, and costs associated with Clostridium difficile infection. Infect Dis Clin North Am 2015; 29(1): 123-34.
42. Mc Donald LC, Killgore GE, Thompson A, et al. An epidemic, toxic gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353: 2433-41.
43. Salman E, Levent B, Karahan ZC. Antimicrobial susceptibilities and molecular characterization of toxin-positive Clostridium difficile isolates: the first report on the presence of hypervirulent
strains from Turkey. Mikrobiyol Bul 2017; 51(3): 236-46.
44. Henrich TJ, Krakower D, Bitton A, Yokoe DS. Clinical risk factors for severe Clostridium difficile-associated disease. Emerg Infect Dis 2009; 15: 415-22.
45. Razik R, Rumman A, Bahreini Z, McGeer A, Nguyen GC. Recurrence of Clostridium difficile infection in patients with inflammatory bowel disease: the RECIDIVISM Study. Am J Gastroen-
terol 2016; 111: 1141–46.
46. Peng JC, Shen J, Zhu Q, Ran ZH. The impact of Clostridum difficile on surgical rate among ulcerative colitis patients: a systemic review and meta-analysis. Saudi J Gastroenterol 2015; 21:
208–12.
47. Hurley BW, Nguyen CC. The spectrum of pseudomembranous enterocolitis and antibiotic-associated diarrhea. Arch Intern Med 2002; 162: 2177-84.
48. Çelik A, Coşgun S. Clostridium difficile enfeksiyonlarında klinik. (In) Öztürk R (ed) Yeni ve Yeniden Gündeme Gelen İnfeksiyonlar : Clostridium difficile enfeksiyonları . Bilimsel Tıp yayınevi
, Ankara 2005: 25-28.
49. Joainig MM, Gorkiewicz G, Leitner E, et al. Cytotoxic effects of Klebsiella oxytoca strains isolated from patients with antibiotic-associated hemorrhagic colitis or other diseases caused by
infections and from healthy subjeccts. J Clin Microbiol 2010; 48: 817-24.
50. Do AN, Fridkin SK, Yechouron A, Benerjee SN, et al. Risk factors for early reccurent Clostridium difficile-associated diarrhoea. Clin Infect Dis 1998; 26: 954-59.
51. Trinn C, Prabhakar K. Diarrheal diseases in the elderly. Clin Geriatr Med 2007; 23: 833-56.
52. Öztürk R. İshal tanımı. In Öztürk R (ed). İshal. İstanbul Bulaşıcı Hastalıklarla Savaş Derneği Yayın No: 13. İstanbul, 1998: 70-92.
53. Guerrant RL, Van Gilder T, Steiner TS, et al. Practice guidelines for the management of infectious diarrhea. Clin Infect Dis 2001; 32: 331-50.
54. Johal SS, Hammond J, Solomon K, James PD, Mahida YR. Clostridium difficile associated diarrhoea in hospitalised patients: onset in the community and hospital and role of fleksible sigmo-
doskopy. Gut 2004; 53: 673-77.
55. Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces
boulardii. Clin Infect Dis 2000; 31: 1012–17.
56. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease.
JAMA 1994; 271: 1913–18.
57. Wullt M, Hagslatt ML, Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo- controlled trial. Scand J
Infect Dis 2003; 35: 365–67.
58. Johnson S, Lavergne V, Skinner AM, et al. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021
Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis 2021; 73(5): e1029-e1044.
59. Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 2003; 36:
580–85.
60. Bakken JS. Fecal bacteriotherapy for recurrent Clostridium difficile infection. Anaerobe 2009; 15: 285–89.
61. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011; 53:
994–1002.
62. Guo B, Harstall C, Louie T, Veldhuyzen van Zanten S, Dieleman LA. Systematic review: faecal transplantation for the treatment of Clostridium difficile-associated disease. Aliment Pharmacol
Ther 2012; 35: 865–75.
63. US Food and Drug Administration. Important safety alert regarding use of fecal microbiota for transplantation and risk of serious adverse reactions due to transmission of multi-drug resistant orga-
nisms, 2019. [Internet]. Erişim adresi: https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/important-safety-alert-regarding-use-fecal-microbiota-transplantation-and-risk-seri-
ous-adverse.
64. US Food and Drug Administration. Update to March 12, 2020 safety alert regarding use of fecal microbiota for transplantation and risk of serious adverse events likely due to transmission
of pathogenic organisms 2020. [Internet]. Erişim adresi: https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/update-march-12-2020-safety-alert-regarding-use-fe-
cal-microbiota-transplantation-and-risk-serious.
65. US Food and Drug Administration. Safety alert regarding use of fecal microbiota for transplantation and additional safety protections pertaining to SARS-CoV-2 and COVID-19, 2020.[Internet]. Erişim adresi: https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/safety-alert-regarding-use-fecal-microbiota-transplantation-and-additional-safety-pro-
tections.
66. DeFilipp Z, Bloom PP, Torres Soto M, et al. Drug-resistant E.coli bacteremia transmitted by fecal microbiota transplant. N Engl J Med 2019; 381: 2043–50.
67. Gill HS, Guarner F. Probiotics and human health: a clinical perspective. Postgrad Med J 2004; 80: 516-26.
68. Hawrelak JA, Whitten DL, Myers SP. Is Lactobacillus rhamnosus GG effective in preventing the onset of antibiotic-associated diarrhoea: a systematic review. Digestion 2005; 72: 51-56.
69. Dendukuri N, Costa V, McGregor M, Brophy JM. Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review. CMAJ 2005; 173: 167-70.
70. Surawicz CM. Probiotics, antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in humans. Best Practice Research Clin Gastroenterol 2003; 17: 775-83.
71. Beniwal RS, Arena VC, Thomas L, et al. A randomized trial of yogurt for prevention of antibiotic-associated diarrhea. Dig Dis Sci 2003; 48: 2077-82.
72. Razim A, Gorska S, Gamian A. Non-toxin-based Clostridioides difficile vaccination approaches. Pathogens 2023; 12(2): 235.